A Phase II Randomized Trial Of Olaparib Versus Olaparib Plus Tremelimumab In Platinum-Sensitive Recurrent Ovarian Cancer

Protocol No
NRG-GY021
Principal Investigator
William Bradley
Phase
II
Summary
This phase II trial studies how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back (recurrent). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib and tremelimumab together may work better than olaparib alone in treating patients with ovarian, fallopian tube, or peritoneal cancer.
Description
To assess how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: